Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3127804 with or without ramucirumab in advanced solid tumors
NCT02597036Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2015
- Primary completion
- Nov 2017
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of zansecimab in solid tumor (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Recommended Phase 2 Dose of LY3127804 Monotherapy and in Combination With Ramucirumab at 4 weeks. Started Nov 2015; status: terminated.
02
Drugs
zansecimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02597036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597036.